Ascendis Pharma A/S (BVMF:A1SN34)

Ascendis Pharma Statistics

Total Valuation

Ascendis Pharma has a market cap or net worth of BRL 75.19 billion. The enterprise value is 77.06 billion.

Market Cap	75.19B
Enterprise Value	77.06B

Important Dates

The last earnings date was Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+5.21%
Shares Change (QoQ)	+5.74%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	20.17%
Float	62.11M

Valuation Ratios

The trailing PE ratio is 25.21 and the forward PE ratio is 17.79.

PE Ratio	25.21
Forward PE	17.79
PS Ratio	14.44
PB Ratio	25.62
P/TBV Ratio	25.81
P/FCF Ratio	277.83
P/OCF Ratio	206.66
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	25.83
EV / Sales	15.39
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	284.75

Financial Position

The company has a current ratio of 1.00, with a Debt / Equity ratio of 1.84.

Current Ratio	1.00
Quick Ratio	0.68
Debt / Equity	1.84
Debt / EBITDA	421.76
Debt / FCF	19.93
Interest Coverage	-0.13

Financial Efficiency

Return on equity (ROE) is 332.65% and return on invested capital (ROIC) is -0.90%.

Return on Equity (ROE)	332.65%
Return on Assets (ROA)	-0.60%
Return on Invested Capital (ROIC)	-0.90%
Return on Capital Employed (ROCE)	-1.68%
Weighted Average Cost of Capital (WACC)	7.12%
Revenue Per Employee	4.38M
Profits Per Employee	2.51M
Employee Count	1,189
Asset Turnover	0.57
Inventory Turnover	0.31

Taxes

Income Tax	-3.99B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.58% in the last 52 weeks. The beta is 0.49, so Ascendis Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.49
52-Week Price Change	+19.58%
50-Day Moving Average	66.65
200-Day Moving Average	n/a
Relative Strength Index (RSI)	59.01
Average Volume (20 Days)	261

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.57

Income Statement

In the last 12 months, Ascendis Pharma had revenue of BRL 5.21 billion and earned 2.98 billion in profits. Earnings per share was 48.33.

Revenue	5.21B
Gross Profit	4.64B
Operating Income	-88.75M
Pretax Income	-1.01B
Net Income	2.98B
EBITDA	-61.50M
EBIT	-88.75M
Earnings Per Share (EPS)	48.33

Balance Sheet

The company has 3.45 billion in cash and 5.39 billion in debt, with a net cash position of -1.95 billion.

Cash & Cash Equivalents	3.45B
Total Debt	5.39B
Net Cash	-1.95B
Net Cash Per Share	n/a
Equity (Book Value)	2.94B
Book Value Per Share	47.26
Working Capital	-26.60M

Cash Flow

In the last 12 months, operating cash flow was 363.84 million and capital expenditures -93.19 million, giving a free cash flow of 270.64 million.

Operating Cash Flow	363.84M
Capital Expenditures	-93.19M
Depreciation & Amortization	26.41M
Net Borrowing	-160.11M
Free Cash Flow	270.64M
FCF Per Share	n/a

Margins

Gross margin is 89.04%, with operating and profit margins of -1.70% and 57.28%.

Gross Margin	89.04%
Operating Margin	-1.70%
Pretax Margin	-19.32%
Profit Margin	57.28%
EBITDA Margin	-1.18%
EBIT Margin	-1.70%
FCF Margin	5.20%

Dividends & Yields

Ascendis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.21%
Shareholder Yield	-5.21%
Earnings Yield	3.97%
FCF Yield	0.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascendis Pharma has an Altman Z-Score of -1.05 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.05
Piotroski F-Score	5